Molecular Diagnostics For Sexually Transmitted Diseases Market Report 2026

Molecular Diagnostics For Sexually Transmitted Diseases Market Overview

• Molecular Diagnostics For Sexually Transmitted Diseases market size has reached to $3.67 billion in 2025 • Expected to grow to $6.05 billion in 2030 at a compound annual growth rate (CAGR) of 10.4% • Growth Driver: Rising Prevalence Of STIs Fueling The Growth Of The Market Due To Increasing Need For Early And Accurate Detection • Market Trend: Innovation In Rapid Point-Of-Care PCR Devices Enhancing STI Diagnostic Accessibility And Efficiency • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Molecular Diagnostics For Sexually Transmitted Diseases Market?

Molecular diagnostics for sexually transmitted diseases involve techniques that detect the genetic material of infectious organisms, such as DNA or RNA, to identify the presence of pathogens. These methods are known for their high accuracy and sensitivity, enabling the detection of infections even when symptoms are not present. By analyzing the molecular structure of the pathogens, these diagnostics provide reliable identification, contributing to faster diagnosis. The main product types of molecular diagnostics for sexually transmitted diseases include instruments and services, consumables, and software. Instruments refer to the diagnostic devices and platforms used for detecting pathogens, while services include laboratory testing, sample processing, and diagnostic result interpretation provided by healthcare or diagnostic companies. These diagnostics utilize various technologies such as laboratory testing and point-of-care testing and are applied in a range of applications, including chlamydia trachomatis (CT) or neisseria gonorrhoeae (NG) testing, syphilis testing, gonorrhea testing, herpes simplex virus (HSV) testing, human papillomavirus (HPV) testing, human immunodeficiency virus (HIV) testing, trichomonas, ureaplasma and mycoplasma, and others.

What Is The Molecular Diagnostics For Sexually Transmitted Diseases Market Growth Forecast?

The molecular diagnostics for sexually transmitted diseases market size is expected to see rapid growth in the next few years. It will grow to $6.05 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to technological advancements in automated pcr and nucleic acid extraction, expansion of point-of-care molecular diagnostics, increasing healthcare infrastructure in developing regions, rising adoption of laboratory information management systems (lims), growing investment in r&d for rapid and multiplexed diagnostic assays. Major trends in the forecast period include increasing adoption of nucleic acid-based testing methods, expansion of point-of-care molecular diagnostic solutions, rising demand for rapid and accurate std detection, integration of molecular diagnostics with laboratory information systems, growth in automated pcr and high-throughput diagnostic platforms.

What Is The Driver Of The Molecular Diagnostics For Sexually Transmitted Diseases Market?

The rising prevalence of sexually transmitted infections is expected to propel the growth of the molecular diagnostics for sexually transmitted diseases market going forward. Sexually transmitted infections (STIs) refer to infections caused by bacteria, viruses, or parasites that are transmitted through sexual contact, affecting the reproductive and urinary systems. The prevalence of sexually transmitted infections is increasing primarily due to the inconsistent use of protection methods. This lack of protection facilitates the easier transmission of infections among sexually active individuals. Molecular diagnostics for sexually transmitted infections (STIs) play a critical role in managing these infections by enabling early and accurate detection of pathogens, even in asymptomatic individuals, facilitating timely treatment, reducing disease transmission, and improving overall patient outcomes. For instance, in June 2024, according to the UK Health Security Agency (UKHSA), a UK-based government agency, in 2023, there were 401,800 new STI diagnoses in England, marking a 4.7% increase compared to the 383,789 cases reported in 2022. Therefore, a rising prevalence of sexually transmitted infections is driving the growth of the molecular diagnostics for sexually transmitted diseases industry.

Key Players In The Global Molecular Diagnostics For Sexually Transmitted Diseases Market

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMérieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, Solone Life Sciences India (P) Ltd.

Global Molecular Diagnostics For Sexually Transmitted Diseases Market Trends and Insights

Major companies operating in the molecular diagnostics for sexually transmitted diseases market are focusing on developing innovative solutions, such as rapid point-of-care polymerase chain reaction (PCR) devices, to improve diagnostic speed, accuracy, and accessibility. Rapid point-of-care polymerase chain reaction (PCR) devices are portable molecular diagnostic tools that combine sample preparation, amplification, and detection into a single, compact unit, enabling timely and highly sensitive pathogen detection outside traditional laboratory settings. For instance, in March 2025, Visby Medical, a US-based diagnostic technology company, launched the Visby Medical Women’s Sexual Health Test. The product is a single-use, handheld PCR device designed to identify chlamydia, gonorrhea, and trichomoniasis from vaginal samples within 30 minutes. It operates without the need for external instrumentation or cold-chain logistics, features an integrated amplification system, and provides lab-quality results directly at the point of care to support immediate clinical decisions. The test is authorized for prescription home use, making it the first U.S. Food and Drug Administration (FDA)-cleared molecular diagnostic test for multiple sexually transmitted infections (STIs) that can be used outside clinical settings. This launch reflects a shift toward decentralized diagnostic solutions that increase accessibility, especially in underserved or remote populations.

What Are Latest Mergers And Acquisitions In The Molecular Diagnostics For Sexually Transmitted Diseases Market?

In December 2024, OraSure Technologies, a US-based provider of point-of-care and home diagnostic solutions, acquired Sherlock Biosciences for an undisclosed amount. With this acquisition, OraSure aimed to expand its molecular diagnostics portfolio in sexual health by integrating Sherlock’s over-the-counter chlamydia trachomatis and neisseria gonorrhoeae self-test, which delivers laboratory-quality results in under 30 minutes using a clustered regularly interspaced short palindromic repeats-based and isothermal amplification-based platform. Sherlock Biosciences is a US-based biotechnology company specializing in molecular diagnostics for sexually transmitted diseases.

What Defines the Molecular Diagnostics For Sexually Transmitted Diseases Market?

The molecular diagnostics for sexually transmitted diseases market consists of revenues earned by entities by providing services such as test development, sample collection, nucleic acid amplification, and point of care diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The molecular diagnostics for sexually transmitted diseases market also includes sales of polymerase chain reaction kits, isothermal nucleic acid amplification kits, clustered regularly interspaced short palindromic repeats-based tests, and instrument-free molecular diagnostic systems. values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Molecular Diagnostics For Sexually Transmitted Diseases Market Report 2026?

The molecular diagnostics for sexually transmitted diseases market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the molecular diagnostics for sexually transmitted diseases industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.